Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoTSE:4506 -0.97%66 Days Inventory is 149.25 as of Mar. 2026, which is 27% below its 10-year median of 205.02. GuruFocus rates TSE:4506 with a GF Score™ of 66/100 and a GF Value™ of 円837.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 50.6% on this metric.
The historical rank and industry rank for Sumitomo Pharma Co's Days Inventory or its related term are showing as below:
TSE:4506'
s Days Inventory Range Over the Past 10 Years
Min: 161.47 Med: 205.02 Max: 302.43
Current: 161.47
During the past 13 years, Sumitomo Pharma Co's highest Days Inventory was 302.43. The lowest was 161.47. And the median was 205.02.
TSE:4506's Days Inventory is ranked better than 50.6% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs TSE:4506: 161.47
Sumitomo Pharma Co's Days Inventory
declined
from Mar. 2025 (231.91) to Mar. 2026 (149.25).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sumitomo Pharma Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.61.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sumitomo Pharma Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.79.
Sumitomo Pharma Co (TSE:4506) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sumitomo Pharma Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sumitomo Pharma Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sumitomo Pharma Co Days Inventory Related Terms
Sumitomo Pharma Co Days Inventory Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (TSE:4506) has a Days Inventory of 149.25 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sumitomo Pharma Co and its competitors. This is 27% below median its historical median of 205.02. Over the past decade, Sumitomo Pharma Co's Days Inventory has ranged from 161.47 to 302.43. According to the industry distribution chart, Sumitomo Pharma Co ranks #456 out of 923 companies in the Drug Manufacturers industry, placing it in the top 49.4%.
Is Sumitomo Pharma Co's Days Inventory too high?
Sumitomo Pharma Co's current Days Inventory of 149.25 is 27% below median its 10-year median of 205.02. Over the past 10 years, this metric has ranged from a low of 161.47 to a high of 302.43. The Drug Manufacturers industry median Days Inventory is 164.38. Sumitomo Pharma Co's value of 149.25 is 9.2% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #456 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sumitomo Pharma Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #456 out of 923 companies for Days Inventory. This puts Sumitomo Pharma Co in the upper half of its industry. The industry median Days Inventory is 164.38. Sumitomo Pharma Co's value of 149.25 is 9.2% below this benchmark. Historically, Sumitomo Pharma Co's own Days Inventory has ranged from 161.47 to 302.43 over the past decade. While the company's 10-year median is 205.02 vs. the industry median of 164.38, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current Days Inventory of 149.25 is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current Days Inventory is 149.25, which is 27% below median its own 10-year median of 205.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円837.87, compared to a current price of 円1,329.00 — trading 58.6% above its estimated fair value. The current Days Inventory is 149.25, which is 27% below median its 10-year median of 205.02 and 9.2% below the Drug Manufacturers industry median of 164.38. Sumitomo Pharma Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Days Inventory is 149.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of 円1,329.00 is trading 58.6% above its estimated GF Value™ of 円837.87.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for TSE:4506:
Days Inventory: 149.25 (27% below median its 10-year median of 205.02)
GF Value™: 円837.87 vs. price of 円1,329.00 (58.6% above fair value)
Industry Position: 9.2% below the Drug Manufacturers median (#456 of 923)
No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for TSE:4506
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4506 has been successfully added to your 
